ERBB2 and breast cancer: Research carried out on MDA-MB-231 cells showed that the overexpression of miR-335 could increase the sensitivity of triple-negative breast cancer (BC with negative immunohistochemical results of estrogen receptor, progesterone receptor, and proto-oncogene HER-2) to cisplatin and doxorubicin, which improved the efficacy of chemotherapy [87].